Antineoplastic Nilotinib CAS 641571-10-0 Raw Materials Powder

CAS: 641571-10-0

MF: C28H22F3N7O

Specification​: 99% min Nilotinib Powder

Sample: Nilotinib Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

Nilotinib Powder Usage and Synthesis .

Nilotinib (Tasigna) is a novel targeted oncology drug that is a tyrosine kinase inhibitor used to treat patients with chronic granulomatous leukemia (CML) who are resistant to Gleevec (imatinib) with significant efficacy. Gleevec is a drug of choice developed by Novartis for the treatment of chronic granulocytic leukemia (CML). Nilotinib is derived from the improved molecular structure of imatinib and has a stronger selectivity for BCR-ABL kinase activity. It inhibits tyrosine kinase 30-fold more strongly than imatinib and can inhibit the kinase activity of BCR-ABL mutant types resistant to imatinib. It also inhibits KIT and PDGFR kinase activities.

Application/Function of Nilotinib Powder.

Taken twice daily, nilotinib inhibits the production of cancer cells containing abnormal chromosomes by targeting the Bcr-Abl protein, which is produced by cells containing abnormal Philadelphia chromosomes and is thought to be an important factor in the overproliferation of oncogenic leukocytes in patients with CML. In clinical trials, 42% of patients with Gleevec-resistant chronic-phase Philadelphia chromosome-positive (Ph+) CML showed a reduction or disappearance of abnormal chromosomes after treatment with Tasigna; the same results were achieved in 31% of patients in the accelerated phase.

Production method of Nilotinib Powder .

Positive results based on a pivotal Phase II clinical trial designed to evaluate oral formulations of nilotinib against imatinib mesylate or its treatment of patients with apparently toxic slow- and accelerated-phase Ph+ CML: high efficacy, good tolerability, and manageable safety profile. Switzerland has granted the first worldwide approval for Novartis' potent and novel targeted therapy, nilotinib oral tablet (trade name: Tasigna), for the treatment of chronic granulocytic leukemia (CML), a blood cancer, that is ineffective or intolerant to life-threatening treatment with imatinib mesylate (trade name: Glivec). Dosage specifications: Nilotinib 300mg/tablet, 400mg/tablet.

Imatinib mesylate is a new generation targeted anticancer agent with inhibitory effect on platelet-derived growth factor (PDGF) receptor protein kinase, which is one of the most effective of all antitumor agents, with an efficiency of over 94% for the treatment of newly diagnosed chronic granulocytic leukemia (CML) and cytological remission in 76% of patients, with the following main indications:

• 1, Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) adult chronic granulocytic leukemia in the chronic phase.
• 2, Treatment of Philadelphia chromosome-positive chronic granulocytic leukemia in the acute and accelerated phases.
• 3, Treatment of chronic granulocytic leukemia in the chronic phase that has been treated with interferon.
• 4, Treatment of pediatric chronic granulocytic leukemia that has relapsed after myelosuppression or has failed to respond to treatment with interferon.
• 5, Treatment of inoperable or metastatic malignant gastrointestinal mesenchymal tumors that are positive for KIT (CD117).